A prospective , multicenter , single-blind trial comparing the Lutonix DCB ( Bard Lutonix ; New Hope , MN ) versus PTA for treatment of femoropopliteal PAD ( LEVANT @ ) is the first US-based @:@ randomized controlled trial of @ patients with femoral-popliteal PAD designed to demonstrate superior efficacy and noninferior safety of a novel paclitaxel DCB compared with PTA .